The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda
Open accessPublished version of a preprint
Abstract
Retrospective studies that may be impractical to confirm prospectively suggest that diabetics treated with metformin have a substantially reduced cancer burden compared with other diabetics. It is unclear if this reflects a chemopreventive effect, an effect on transformed cells, or both. It also remains to be established if these data have relevance to people without diabetes. Laboratory models, however, provide independent impressive evidence for the activity of metformin and other biguanides in both cancer treatment and chemoprevention. Investigations of mechanisms of action of biguanides have revealed considerable complexity and have identified important gaps in knowledge that should be addressed to ensure the optimal design of clinical trials of these agents. Such trials may define important new indications for biguanides in the prevention and/or treatment of many common cancers. Cancer Prev Res; 3(9); 1060–5. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, our results indicate that PTEN-negative tumors seem resistant to the anticancer effect of metformin, which may be related to another anticancer mechanism of metformin involving adenosine monophosphate-activated protein kinase (AMPK) [3,18].”
From Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08/14). (2026) · cites this paper as [18]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Kahn, B. B., Alquier, T., Carling, D., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.12.003 · Cited by 2,799
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Self-citationInsulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Self-citationThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus
Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y.-B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferré, P., Birnbaum, M. J., et al. (2004) · Nature · doi:10.1038/nature02440 · Cited by 1,637
Cited by
Sorted by citations
Items 201–239 of 239
Adiponectin-Based Therapeutics for Cancer Treatment
Li, D., Cao, H., Chen, J., Liu, M. R., & Wang, Y. (2017) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681084817117040007 · Cited by 1
Chemoprevention in Oral Cancer
Loomans-Kropp, H. A., & Szabo, E. M. (2020) · Textbooks in contemporary dentistry · doi:10.1007/978-3-030-32316-5_18 · Cited by 1
Preston, M. A., Batista, J. L., Breau, R. H., Adami, H., & Sørensen, H. T. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.005 · Cited by 1
Lippman, S. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0113 · Cited by 1
Meireles, C. G. (2015) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2015.02.d.18424
“A partir de então, diversos outros estudos verificaram associações entre o uso de antidiabéticos orais e redução da progressão ou incidência do câncer e sugeriram que a metformina seria o antidiabético oral que tinha efeitos sobre a progressão do câncer (60, 61, 63-66).”
BackgroundThe role of insulin and IGF2 signalling on metabolic pathways in prostate cancer progression
Lubik, A. A. (2011) · Faculty of Science and Technology; Institute of Health and Biomedical Innovation
New Developments in Urology: Urology Update 2014
Herschorn, S. (2015) · Canadian Urological Association Journal · doi:10.5489/cuaj.2668
DIRECT EFFECTS OF METFORMIN ON PI3K AND RAS SIGNALING IN ENDOMETRIAL CANCER
Iglesias, & David, A. (2012)
Berstein, L. M. (2012) · Obesity and metabolism · doi:10.14341/omet2012211-16
Implicating insulin in neoplastic growth and metabolism
Mashhedi, H. (2011) · doi:10.82308/55456
Anti-diabetic treatment and cancer occurrence among patients with type II diabetes mellitus
Qiu, H. (2011) · doi:10.7282/t3930s81
“Preclinical studies have demonstrated that metformin can inhibit the growth of cancer cells in vitro and in vivo [20].”
BackgroundThe insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology
Pollak, M. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.012
Self-citationPrimärprävention des Mammakarzinoms
Thor-Wiedemann, S., & Wiedemann, G. J. (2013)
Wu, G., Zhang, X., Luo, Z., Yan, J., Pan, S., Ying, X., & Zhang, G.-F. (2015)
Risk-Reducing (Chemopreventive) Agents in Breast Cancer Prevention
Gronich, N., & Rennert, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-27135-4_8
Mayer, M. (2016) · TSpace (University of Toronto)
Metformin and Prostate Cancer among Diabetic Men
Margel, D. (2014) · TSpace (University of Toronto)
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model
Alves-Silva, A. B., Fenerich, B. A., Fonseca, N. P., Fernandes, J. C., Coelho-Silva, J. L., Pereira‐Martins, D. A., Bianco, T. M., Scheucher, P. S., Rego, E. M., Chahud, F., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01212-y · Cited by 1
“The choice for phenformin was based on the rationale that biguanides have potential antineoplastic effects [9, 16, 17].”
Background(2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834f4ea3
Platz, E. A. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.07.014
Bridges, D. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733574568.793549314
Han, X. (2022) · Journal of Tumor Science Research · doi:10.47363/jtsr/2022(1)106
Wanjari, P. J., Rath, A., Sathe, R. Y., & Bharatam, P. V. (2023) · Journal of Molecular Modeling · doi:10.1007/s00894-023-05538-z
Biguanide-PROTACs: Modulating Mitochondrial Proteins in Pancreatic Cancer CellsPreprint
Vatté, J., Bourdeau, V., Ferbeyre, G., & Schmitzer, A. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.17.585436
Head and Neck Cancer and Lipid Levels: New Horizons in Pathophysiology and Treatments
Yiğin, A. K., Ağırbaşlı, D., & Ağırbaşlı, M. A. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_351
Repurposing Metformin: A New Frontier in Cancer Therapy
Patil, S., Sawant, S., & Kamble, M. C. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-29680
Metformin as a Senotherapeutic Agent
Turgut, Ş., Atasever, E., Andican, G., & Çakatay, U. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-11608-6_16
Drug Repurposing of Aspirin and Metformin with Special Reference to Colorectal Cancer Mitigation
Talukder, P., Mukherjee, A., Sinha, B., Mishra, M., Datta, S., & Sengupta, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814533126010010
Rôle des calpaïnes extracellulaires dans la progression des adénocarcinomes lépidiques
Ruppert, A.-M. (2015) · theses.fr (ABES) · doi:10.70675/6082601cze5b6z41e9zb588zf90c85ff07c9
Ning, Y., Yang, X., Chen, L., Yi, J., Li, J., Lin, Y., Mu, L., & Xu, C. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109847
Ansar, F., Zafar, U., Shafqat, H., Jabeen, A., & Masood, A. K. (2026) · Qeios · doi:10.32388/vj831z
Yiğittürk, G., Çetinavcı, D., Önal, M. Ö., Elbe, H., & Öztürk, F. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2671721
“Metformin and phenformin are well-known biguanide compounds widely used in the management of type ii diabetes. their primary mode of action involves inhibition of mitochondrial complex i, resulting in downstream aMPK activation and improved insulin sensitivity [14].”
Dual Metabolic Targeting of Cancer: Lessons from Metformin and 2-Deoxy-D-Glucose Combinations
Zeljković, V., Minić, S., Mladenović, M., Milenković, D., Marković, Z., Soldatović, T., Kunkin, V., & Karaman, M. A. (2026) · Cancers · doi:10.3390/cancers18162537
Çiçek, İ. B., & Küçükakçalı, Z. (2026) · ODÜ Tıp Dergisi · doi:10.56941/odutip.2005806
Rivera-Escareño, D., Cadena-Íñiguez, J., Flores, D. A., Loera-Alvarado, G., Aguilar-Galaviz, L., Ortega-Amaro, M. A., Peredo–Rivera, E., Trejo-Téllez, B. I., Aguíñiga-Sánchez, I., & Santiago‐Osorio, E. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017529
Fakhri, F., Alkhairi, Z., Sarhan, T., Imran, G., Imran, L., Moola, R., Darwish, R., & Al‐Majmuei, A. (2026) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-026-01165-w
De la stéatohépatite non alcoolique au carcinome hépatocellulaire : mécanismes physiopathologiques
Desbois‐Mouthon, C. (2011) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(11)70184-5
Metadata
- Authors
- Pollak, M.
- Affiliations
- Author's Affiliation: Department of Oncology, McGill University and Jewish General Hospital, Montreal, Quebec, Canada
- Venue
- Cancer Prevention Research
- Published
- 2010-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 1060-1065
- ISSN
- 1940-6207 (ISSN-L)
- 1940-6215
- PMC
- PMC2954412
- OpenAlex
- W2165189414
- Cited by
- 240
- References
- 56
- Citations by year
- 2026: 12 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 9 · 2020: 5 · 2019: 12 · 2018: 11 · 2017: 11 · 2016: 8 · 2015: 23 · 2014: 14 · 2013: 23 · 2012: 44
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Prevention Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Prostate Cancer Foundation
- McGill University
- Prostate Cancer Canada
- National Institutes of Health (5r01ca101008-02)
- Canadian Cancer Society Research Institute
- National Cancer Institute (R01 CA101008)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- metformin, biguanides, chemoprevention, cancer therapy, diabetes mellitus, mechanism of action, clinical trial design, laboratory model
- MeSH terms
- Animals, Antineoplastic Agents, Biguanides, Humans, Hypoglycemic Agents, Medical Oncology, Metformin, Neoplasms, Biomedical Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
